187 related articles for article (PubMed ID: 12244089)
1. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease.
Dixon RM; Bradley KM; Budge MM; Styles P; Smith AD
Brain; 2002 Oct; 125(Pt 10):2332-41. PubMed ID: 12244089
[TBL] [Abstract][Full Text] [Related]
2. Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study.
Schott JM; Frost C; MacManus DG; Ibrahim F; Waldman AD; Fox NC
Brain; 2010 Nov; 133(11):3315-22. PubMed ID: 20739347
[TBL] [Abstract][Full Text] [Related]
3. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
[TBL] [Abstract][Full Text] [Related]
4. Hippocampal metabolites and memory performances in patients with amnestic mild cognitive impairment and Alzheimer's disease.
Watanabe T; Shiino A; Akiguchi I
Neurobiol Learn Mem; 2012 Mar; 97(3):289-93. PubMed ID: 22390859
[TBL] [Abstract][Full Text] [Related]
5. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study.
Schuff N; Amend D; Ezekiel F; Steinman SK; Tanabe J; Norman D; Jagust W; Kramer JH; Mastrianni JA; Fein G; Weiner MW
Neurology; 1997 Dec; 49(6):1513-21. PubMed ID: 9409338
[TBL] [Abstract][Full Text] [Related]
6. Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment.
Foy CM; Daly EM; Glover A; O'Gorman R; Simmons A; Murphy DG; Lovestone S
Brain Topogr; 2011 Oct; 24(3-4):316-22. PubMed ID: 21298332
[TBL] [Abstract][Full Text] [Related]
7. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
Modrego PJ; Pina MA; Fayed N; Díaz M
CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
[TBL] [Abstract][Full Text] [Related]
8. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Pina MA
Am J Psychiatry; 2005 Apr; 162(4):667-75. PubMed ID: 15800137
[TBL] [Abstract][Full Text] [Related]
9. Volumetric MRI and 1H MRS study of hippocampus in unilateral MCAO patients: relationship between hippocampal secondary damage and cognitive disorder following stroke.
Tang X; Wang C; Xia L; Zhu W; Zhao L; Zhu W
Eur J Radiol; 2012 Oct; 81(10):2788-93. PubMed ID: 21945401
[TBL] [Abstract][Full Text] [Related]
10. Using proton magnetic resonance spectroscopy to identify mild cognitive impairment.
Wang T; Xiao S; Li X; Ding B; Ling H; Chen K; Fang Y
Int Psychogeriatr; 2012 Jan; 24(1):19-27. PubMed ID: 21676281
[TBL] [Abstract][Full Text] [Related]
11. Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis.
Wang H; Tan L; Wang HF; Liu Y; Yin RH; Wang WY; Chang XL; Jiang T; Yu JT
J Alzheimers Dis; 2015; 46(4):1049-70. PubMed ID: 26402632
[TBL] [Abstract][Full Text] [Related]
12. Correlation between hippocampal volumes and proton magnetic resonance spectroscopy of the posterior cingulate gyrus and hippocampi in Alzheimer's disease.
Park EJ; Lyra KP; Lee HW; Caramelli P; Otaduy MCG; Leite CC
Dement Neuropsychol; 2010; 4(2):109-113. PubMed ID: 29213672
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C
Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544
[TBL] [Abstract][Full Text] [Related]
14. Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease.
Watanabe T; Shiino A; Akiguchi I
Dement Geriatr Cogn Disord; 2008; 26(1):89-100. PubMed ID: 18617735
[TBL] [Abstract][Full Text] [Related]
15. Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease.
Lamar M; Foy CML; Beacher F; Daly E; Poppe M; Archer N; Prasher V; Murphy KC; Morris RG; Simmons A; Lovestone S; Murphy DGM
Neuroimage; 2011 Jul; 57(1):63-68. PubMed ID: 21504795
[TBL] [Abstract][Full Text] [Related]
16. Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in Alzheimer's disease: diverging behavior at three different brain regions.
Bittner DM; Heinze HJ; Kaufmann J
J Alzheimers Dis; 2013; 36(1):155-63. PubMed ID: 23579327
[TBL] [Abstract][Full Text] [Related]
17. Atrophy of the hippocampus, parietal cortex, and insula in Alzheimer's disease: a volumetric magnetic resonance imaging study.
Foundas AL; Leonard CM; Mahoney SM; Agee OF; Heilman KM
Neuropsychiatry Neuropsychol Behav Neurol; 1997 Apr; 10(2):81-9. PubMed ID: 9150507
[TBL] [Abstract][Full Text] [Related]
18. The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy.
Shiino A; Watanabe T; Shirakashi Y; Kotani E; Yoshimura M; Morikawa S; Inubushi T; Akiguchi I
J Cereb Blood Flow Metab; 2012 May; 32(5):805-15. PubMed ID: 22314267
[TBL] [Abstract][Full Text] [Related]
19. Single voxel magnetic resonance spectroscopy at 3 Tesla in a memory disorders clinic: early right hippocampal NAA/Cr loss in mildly impaired subjects.
Caserta MT; Ragin A; Hermida AP; Ahrens RJ; Wise L
Psychiatry Res; 2008 Nov; 164(2):154-9. PubMed ID: 18930637
[TBL] [Abstract][Full Text] [Related]
20. Effects of donepezil on brain morphometric and metabolic changes in patients with Alzheimer's disease: A DARTEL-based VBM and (1)H-MRS.
Moon CM; Kim BC; Jeong GW
Magn Reson Imaging; 2016 Sep; 34(7):1008-16. PubMed ID: 27131829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
